Control of HIV-1 infection by soluble factors of the immune response

Nature Reviews Microbiology

Volumn 2, Issue 5, 2004, Pages 401-413

  DeVico, Anthony L ^a   Gallo, Robert C ^a  

^a UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; BETA INTERFERON; CD16 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CYTOKINE; DEFENSIN; DOUBLE STRANDED RNA; HEPATITIS B VACCINE; HEPATITIS C VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYDROXYUREA; INTERFERON; JANUS KINASE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RANTES; RAPAMYCIN; STAT PROTEIN; STROMAL CELL DERIVED FACTOR 1; TUMOR NECROSIS FACTOR; UROKINASE; VIRUS ANTIGEN; MACROPHAGE INFLAMMATORY PROTEIN 1;

ANTIGEN PRESENTATION; ANTIVIRAL ACTIVITY; B LYMPHOCYTE; CELL COMMUNICATION; CELL INTERACTION; CELL KILLING; CYTOKINE RELEASE; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG DESIGN; DRUG TARGETING; EXPERIMENTAL MODEL; GRANULOCYTE; HELPER CELL; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HOST CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOREGULATION; MACROPHAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; MICROBIAL DIVERSITY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW; T LYMPHOCYTE; VIROGENESIS; VIRUS IMMUNITY; VIRUS INHIBITION; ANIMAL; CD8+ T LYMPHOCYTE; IMMUNOLOGY; VIROLOGY; VIRUS REPLICATION;

HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; JANUS;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HIV-1; HUMANS; MACROPHAGE INFLAMMATORY PROTEIN-1; MICE; RANTES; VIRUS REPLICATION;

EID: 2442595897     PISSN: 17401526     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrmicro878     Document Type: Review

References (185)

1. Biron, C. A., Nguyen, K. B., Pien, G. C., Cousens, L. P. & Salazar-Mather, T P. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu. Rev. Immunol. 17, 189-220 (1999).
2. Biron, C. A. & Brossay, L. NK cells and NKT cells in innate defence against viral infections. Curr. Opin. Immunol. 13, 458-464 (2001).
3. Wallace, M., Malkovsky M. & Carding, S. R. γ/δ T lymphocytes in viral infections. J. Leukoc. Biol. 58, 277-283 (1995).
4. Welsh, R. M. et al. α β and γ δ T-cell networks and their roles in natural resistance to viral infections. Immunol. Rev. 159, 79-93 (1997).
5. Selin, L. K., Santolucito, P. A., Pinto, A. K., Szomolanyi-Tsuda, E. & Welsh, R. M. Innate immunity to viruses: control of vaccinia virus infection by γ δ T cells. J. Immunol. 166 6784-6794 (2001).
6. Isaacs, A. & Lindemann, J. Virus interference I. The interferon. Proc. Natl Acad. Sci. USA 147, 258 (1957).
7. Vilcek J. & Sen, G. C. in Virology (eds Fields B. N., Knipe, D. M. & Howley, P. M.) 375 (Lippencott-Raven, Philadelphia, 1996).
8. Kalvakolanu, D. V. & Borden, E. C. An overview of the interferon system: signal transduction and mechanism of action. Cancer Invest. 14, 25-53 (1996).
9. Stark, G. R., Kerr, I. M., Williams, B. R., Silverman, R. H. & Schreiber, R. D. How cells respond to interferons. Annu. Rev. Biochem. 67. 227-264 (1998).
10. Guidotti, L. G. & Chisari, F. V. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu. Rev. Immunol. 19, 65-91 (2001).
11. Katze, M. G., He, Y. & Gale, M. Viruses and interferon: a fight for supremacy. Nature Rev. Immunol. 2, 675-687 (2002 ).
12. Shirazi, Y. & Pitha, P. M. Intereferon α-mediated inhibition of human immunodeficiency virus type 1 provirus synthesis in T-cels. Virology 193, 303-312 (1993).
13. Shirazi, Y. & Pitha, P. M. Interferon downregulates CXCR4 (fusin) gene expression in peripheral blood mononuclear cells. J. Human. Virol. 2, 69-76 (1998).
14. Guidotti, L. G, Guilhot, S. & Chisari, F. V. Interleukin 2 and interferon α/β negatively regulates hepatitis B virus gene expression in vivo by tumor necrosis factor dependent and independent pathways. J. Virol. 68, 1265-1270 (1994).
15. Gilles, P. N., Fey, G. & Chisari, F. V. Tumor necrosis factor-α negatively regulates hepatitis B virus gene expression in transgenic mice. J. Virol. 66, 3955-3960 (1992).
16. Herbein, G. & O'Brien, W. A. Tumor necrosis factor (TNF)-α and TNF receptors in viral pathogenesis Proc. Soc. Exp. Biol. Med. 223, 241-257 (2000).
17. + T lymphocytes inhibits human immunodeficiency virus type 1 replication through STAT1 activation. J. Virol. 76, 569-581 (2002).
18. Patterson, J. B., Thomis, D. C., Hans, S. L. & Samuel, C. E. Mechanism of interferon action: double stranded RNA-specific adenosine deaminase from human cells is inducible by α and γ interferons. Virology 210, 508-511 (1995).
19. Bovolenta, C. et al. A selective defect of IFN-γ- but not of IFN-α-induced JAK/STAT pathway in a subset of U937 clones prevents the antiretroviral effect of IFN-γ against HIV-1. J. Immunol. 162, 323-330 (1999).
20. Guidotti, L. G. et al. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc. Natl Acad. Sci. USA 91, 3764-3768 (1994).
21. Guidotti, L. G. et al. Intracellular inactivation of the hepatitis B by cytotoxic T lymphocytes. Immunity 4, 25-36 (1996).
22. Guidotti, L. G. The role of cytotoxic T cells and cytokines in the control of hepatitis B virus infection. Vaccine 4, 80-82 (2002).
23. Nakamoto, Y., Guidotti, L. G., Pasquetto, V., Schreiber, R. D. & Chisari, F. V. Differential target cell senstivity to cytotoxic T lymphocyte-activated death pathways in vivo. J. Immunol. 158, 5692-5697 (1997).
24. + T cells correlating with cytotoxic activity in vitro are more effective in antivaccinia virus protection than CD4-dependent interleukins. J. Immunol. 146, 4301-4307 (1991).
25. + T cells. J. Exp. Med. 174, 875-880 (1991).
26. Kundig, T. M., Hengartner, H. & Zinkernagel R. M. T-cell dependent interferon γ exerts an antiviral effect in central nervous system but not in peripheral solid organs. J. Immunol. 150, 2316-2321 (1992).
27. Scherle, P. A., Palladino, G. & Gerhard, W. Mice can recover from pulmonary influenza virus infection in the absence of class I-restricted cytotoxic T cells. J. Immunol. 148, 212-217 (1992).
28. + T-cell-deficient mice survive inoculation with hogh doses of vaccinia virus and exhibit altered IgG mWonses Proc. Natl Acad. Sci. USA 89, 6070-6074 (1992).
29. + T-helper-1 cells in hepatitis B virus transgenic mice. J. Immunol. 159, 2001-2008 (1997).
30. + T-cell subsets during virus infection. Protective capacity depends on effector cytokine secretion and on migratory capability. J. Exp. Med. 191, 2159-2170 (2000 ).
31. + T cells during primary immune responses. Proc. Natl Acad. Sci. USA 100, 15006-15010 (2003).
32. Biron, C. A., Nguyen, K. B., Pien, G. C., Cousens, L. P. & Salazar-Mather, T. P. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu. Rev. Immunol. 17, 189-220 (1999).
33. Orange, J. S., Wang, B., Terhorst, C. & Biron, C. A. Requirement for natural killer cell-produced interferon γ in defense against murine cytomegalovirus infection and enhancement in defense pathway by interleukin 12 administration. J. Exp. Med. 182, 1045-1056 (1996).
34. Orange, J. S. & Biron, C. A. Characterization of early IL-12, IFN-α/β and TNF effects on antiviral state and NK responses during murine cytomegalovirus infection. J. Immunol. 156, 4746-4756 (1996).
35. + patients produce C-C chemokines and inhibit HIV-1 infection. J. Immunol. 161, 6433-6438 (1998).
36. Oliva, A. et al. Natural killer cells from human immunodeficiency virus (HIV)-infected individuals are an important source of CC-chemokines and suppress HIV-1 entry and replication in vitro. J. Clin. Invest. 102, 223-231 (1998).
37. Kottilil, S. et al. Innate immunity in human immunodeficiency virus infection: effect of viremia on natural killer cell function. J. Infect. Dis. 187, 1038-1045 (2003).
38. Lehner, T. et al. The role of γ/δ T cells in generating antiviral factors and β-chemokines in protection against mucosal simian immunodeficiency virus infection. Eur. J. Immunol. 30, 2245-2256 (2000).
39. Lukacher A. E., Braciale, V. L. & Braciale, T. J. In vivo effector function of influenza virus-specific cytotoxic T lymphocyte clones is highly specific. J. Exp. Med. 160, 814-825 (1984 ).
40. McIntyre, K. W., Bukowski, J. F. & Welsh, R. M. Exquisite specificity of adoptive immunization in arenavirus-infected mice. Antiviral Res. 5, 299-305 (1985).
41. Guidotti, L. G. et al. Viral cross talk: intracellular inactivation of the hepatitis B virus during an unrelated infection of the liver. Proc. Natl Acad. Sci. USA 93, 4589-4594 (1996).
42. Tassopoulos, N. et al. Double infections with hepatitis A and B viruses. Liver 5, 348-353 (1985).
43. Van Nunen, A. B., Pontesilli, O., Uytdehaag, F., Osterhaus, A. D. & de Man, R. A. Suppression of hepatitis B virus replication mediated by hepatitis A-induced cytokine production. Liver 21 45-49. (2001).
44. + lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 234, 1563-1566 (1986).
45. + cell anti-HIV activity: noncytolytic suppression of virus replication. AIDS Res. Hum. Retrovir. 8, 1039-1050 (1992).
46. + T cells. Immunol. Today 17, 217-224 (1996).
47. + T cell suppressor activities: dichotomy between infected and uninfected individuals, evolution with progression of disease, and sensitivity to γ irradiation. J. Immunol. 156, 4476-4483 (1996)
48. + cells without eliminating the infected cells from culture. Cell. Immunol. 128, 628-634 (1990).
49. + cells involves a noncytotoxic mechanism. J. Virol. 65, 5921-5927 (1991).
50. + T lymphocytes suppresses HIV replication. Immunology 66 628-630 (1989).
51. + T cells. J. Immunol. 144, 2961-2966 (1990).
52. + cell antiviral factor. Cell. Immunol. 153, 329-343 (1994).
53. + T cells. Science 270, 1811-1815 (1995).
54. Alkhatib, G. et al. CC CKR5: a RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272, 1955-1958 (1996).
55. Dragic, T. et al. HIV-1 entry into CD4 1 cells is mediated by the chemokine receptor CC-CKR-5. Nature 381, 667-673 (1996).
56. Choe, H. et al. The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85, 1135-1148 (1996).
57. Deng, H. K. et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381, 661-666 (1996).
58. Berger, E. A., Murphy, P. M. & Farber, J. M. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17, 657-700 (1999).
59. Gong, W. et al. Monocyte chemotactic protein-2 activates CCR5 and blocks CD4/CCR5-mediated HIV-1 entry/replication. J. Biol. Chem. 273, 4289-4292 (1998).
60. Bertini, R. et al. Identification of MIP-1α/LD78 as a monocyte chemoattractant released by the HTLV-I-transformed cell line MT4. AIDS Res Hum Retrovir. 11, 155-160 (1995).
61. Detheux, M. et al. Natural proteolytic, processing of hemofiltrate CC chemokine 1 generates a potent CC chemokine receptor (CCR)1 and CCR5 agonist with anti-HIV properties. J. Exp. Med. 192, 1501-1508 (2000).
62. Feng, Y., Broder, C. C., Kennedy, P. E. & Berger, E. A. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G-protein coupled receptor. Science 272, 872-877 (1996).
63. Bleul, C. C. et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 382, 829-833 (1996).
64. + cell noncytotoxic anti-HIV response can be blocked by protease inhibitors. Proc. Natl Acad. Sci. USA 100, 3433-3438 (2003 ).
65. + cell granules. Blood 102, 180-183 (2003).
66. Mengozzi, M. et al. Naive CD4 T cells inhibit CD28-costimulated R5 HIV replication in memory CD4 T cells. Proc. Natl Acad. Sci. USA 98, 11644-11649 (2001).
67. + T cell proliferation in HIV-positive patients as a result of CD28 costimulation. Science 272, 1939-1943 (1996 ).
68. Riley, J. L. et al. Intrinsic resistance to T cell infection with HIV type 1 induced by CD28 costimulation. J. Immunol. 158, 5545-5553 (1997).
69. Poccia, F. et al. Phospohoantigen-reactive Vγ9δ2 T lymphocytes suppress in vitro human immunodeficiency virus type 1 replication by cell-released antiviral factors including CC chemokines. J. Infect. Dis. 180, 858-861 (1999).
70. + T cells from exposed uninfected Individuals expressing wild-type CCR-5 allele. J. Exp. Med. 186, 455-460 (1997).
71. Pinto, L. A. et al. Inhibition of human immunodeficiency virus type 1 replication prior to reverse transcription by influenza virus stimulation. J. Virol. 74, 4505-4511 (2000).
72. Pinto, L. A., Sharpe, S., Cohen, D. I. & Shearer, G. M. Alloantigen-stimulated anti-HIV activity. Blood 92, 3346-3354 (1998).
73. Roso, J. F. et al. Oligoclonal CD8 lymphocytes from persons with asymptomatic human immunodeficiency virus (HIV) type 1 infection inhibit HIV-1 replication. J. Infect. Dis. 172, 964-973 (1995).
74. + cells: evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms. J. Virol. 71, 3120-3128 (1997).
75. Wagner, L. et al. β-chemokines are released from HIV-1-specific cytolytic T-cell granules complexed to proteoglycans. Nature 391, 908-911 (1998).
76. Price, D. A. et al. Antigen-specific release of β-chemokines by anti-HIV-1 cytotoxic T lymphocytes. Curr. Biol. 8, 355-358 (1998).
77. Van Baalen, C. A. et al. Kinetics of antiviral activity by human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL) and rapid selection of CTL escape virus in vitro. J. Virol. 72, 6851-6857 (1998).
78. Le Borgne, S., Fevrier, M., Cellebaut, C., Lee, S. P. & Rivers, Y. CD8-cell antiviral factor activity is not restricted to human immunodeficiency virus (HIV)-specific T cells and can block HIV replication after initiation of reverse transcription. J. Virol. 74, 4456-4464 (2000).
79. 2+ signaling. Proc. Natl Acad. Sci. USA 96, 14499-14504 (1999).
80. Sharma, U. K. et al. A novel factor produced by placental cells with activity against HIV-1. J. Immunol. 161, 6404-6412 (1998).
81. Patterson, B. K. et al. Leukemia inhibitory factor inhibits HIV-1 replication and is upregulated in placentae from nontransmitting women. J. Clin. Invest. 107, 287-294 (2001 ).
82. Pal, R. et al. Inhibition of HIV-1 infection by the β-chemokine MDC. Science 278, 695-698 (1997).
83. 2-terminally processed macrophage-derived chemokine (MDC) imply an additional MDC receptor. J. Immunol. 161, 2672-2675 (1998).
84. Cota, M. et al. Selective inhibition of HIV replication in primary macrophages but not T lymphocytes by macrophage-derived chemokine. Proc. Natl Acad. Sci. USA 97, 9162-9167 (2000).
85. Agrawal, L., Vanhorn-Ali, Z. & Akhatib, G. Multiple determinants are involved in HIV coreceptor use as demonstrated by CCR4/CCL22 interaction in peripheral blood mononuclear cells (PBMCs). J. Leukoc. Biol. 72, 1063-1074 (2002).
86. Moriuchi, H. & Moriuchi, M. Dichotomous effects of macrophage-derived chemokine on HIV infection. AIDS 28, 994-996 (1999).
87. + T cells, but not by rIFNβ, rIFNγ, or recombinant tumor necrosis factor-α. J. Acquir. Immune Defic. Syndr. 4, 480-488 (1991).
88. Yamamoto, J. K., Barre-Sinoussi, F., Bolton V., Pedersen, N. C. & Gardner, M. B. Human α- and β-interferon but not γ- suppress the in vitro replication of LAV, HTLV-III, and ARV-2. J. Interferon Res. 6, 143-152 (1986).
89. Hammer, S. M., Gillis, J. M., Groopman, J. E. & Rose, R. M. In vitro modification of human immunodeficiency virus infection by granulocyte-macrophage colony-stimulating factor and γ interferon. Proc. Natl Acad. Sci. USA 83, 8734-8738 (1986).
90. Nakashima, H., Yoshida, T., Harada, S, & Yamamoto, H. Recombinant human interferon γ suppresses HTLV-III replication in vitro. Int. J. Cancer 38, 433-436 (1986).
91. Poli, G., Orenstein, J. M., Kinter, A., Folks, T. M. & Fauci, A. S. Interferon-α but not AZT suppresses HIV expression in chronically infected cell lines. Science 244, 575-577 (1989).
92. Wong, G. H., Krwoka, J. F., Stites, D. P. & Goeddel, D. V. In vitro anti-human immunodeficiency virus activities of tumor necrosis factor-α and interferon-γ. J. Immunol. 40, 120-124 (1988).
93. Williams, G. J. & Colby, C. B. Recombinant human interferon-β suppresses the replication of HIV and acts synergistically with AZT. J. Interferon Res. 9, 709-718 (1989).
94. Gendelman, H. E. et al. Regulation of HIV replication in infected monocytes by IFN-α. Mechanisms for viral restriction. J. Immunol. 145, 2669-2676 (1990).
95. Hartshorn, K. L., Neumeyer, D., Vogt, M. W., Schooley, R. T. & Hirsch, M. S. Activity of interferons α, β, and γ against human immunodeficiency virus replication in vitro. AIDS Res. Hum. Retrovir. 3, 125-133 (1987).
96. Kornbluth, R. S., Oh, P. S., Munis, J. R., Cleveland, P. H. & Richman, D. D. The role of interferons in the control of HIV replication in macrophages. Clin. Immunol. Immunopathol. 54, 200-219 (1990).
97. + T-cell-derived soluble factor(s), but not β-chemokines RANTES, MIP-1α, and MIP-1β, suppress HIV-1 replication in monocyte/macrophages. Proc. Natl Acad. Sci. USA. 93, 15341-15345 (1996).
98. +, T-cell clones correlates with the clinical state of human immunodeficiency virus type 1 (HIV-1)-infected individuals and may be responsible for blocking infection with non-syncytium-inducing HIV-1 in vitro. J. Virol. 72, 876-881 (1998).
99. Leith, J. G. et al. T cell-derived suppressive activity: evidence of autocrine noncytolytic control of HIV type 1 transcription and replication. AIDS Res. Hum. Retrovir. 15, 1553-1561 (1999).
100. Mosoian, A., Teixeira, A., Caron, E., Piwoz, J. & Klotman, M. E. CD8 cell lines isolated from HIV-1-infected children have potent soluble HIV-1 inhibitory activity that differs from β-chemokines. Viral Immunol. 13, 481-495 (2000).
101. + T-cell antiviral factor. J. Biol. Chem. 277, 42352-42357 (2002).
102. Zhang, L. et al. Contribution of human defensin 1, 2,and 3 to the anti-HIV-1 activity of CD8 antiviral factor. Science 298, 995-1000 (2002).
103. Baier, M., Werner, A., Bannert, N., Metzner, K. & Kurth, R. HIV suppression by interleukin-16. Nature 378, 563 (1995).
104. Rugeles, M. T. et al. Ribonuclease is partly responsible for the HIV-1 inhibitory effect activated by HLA alloantigen recognition. AIDS 17, 481-486 (2003).
105. + T cell suppression of syncytia-indicing strains of HIV-1. Proc. Natl Acad. Sci. USA 94, 9842-9847 (1997).
106. Cruikshank, W. W., Kornfeld, H., & Center, D. M. Interleukin-16. J. Leukoc Biol. 67, 757-766 (2000).
107. Mackewicz, C. E., Levy J. A., Cruikshank, W. W., Kornfeld, H. & Center, D. M. Role of IL-16 in HIV replication. Nature 383, 488-489 (1995).
108. Maciaszek, J. W. et al. IL-16 represses HIV-1 promoter activity. J. Immunol. 158, 5-8 (1997).
109. Truong, M. et al. Interleukin-16 inhibits human immunodeficiency virus type 1 entry and replication in macrophages and dendritic cells. J. Virol. 73, 7008-7013 (1999).
110. Wada, M. et al. Amino-terminal fragment of urokinase-type plasminogen activator inhibits HIV-1 replication. Biochem Biophys. Res. Commun. 284, 346-351 (2001).
111. Alfano, M., Sidenius, N., Panzeri, B., Blasi, F. & Poli G. Urokinase-urokinase receptor interaction mediates an inhibitory signal for HIV-1 replication. Proc. Natl Acad. Sci. USA 99, 8862-8867 (2002).
112. Sinha, S., Cheshenko, N., Lehrer, R. I. & Herold, B. C. NP-1, a rabbit α-defensin, prevents the entry and intercellular spread of herpes simplex virus type 2. Antimicrob. Agents Chemother. 47 494-500 (2003).
113. Daher, K. A., Selsted, M. E. & Lehrer, R. I. Direct inactivation of viruses by human granulocyte defensins. J. Virol. 60, 1068-1074 (1986).
114. Bastian, A., & Schafer, H. Human α-defensin 1 (HNP-1) inhibits adenoviral infection in vitro. Regul. Pept. 101, 157-161 (2001).
115. Nakashima, H., Yamamoto, N., Masuda, M. & Fujii, N. Defensins inhibit HIV replication in vitro. AIDS 7, 1129 (1993).
116. Chang, T. L., Francois, F., Mosoian, A. & Klotman, M. E. CAF-mediated human immunodeficiency virus (HIV) type 1 transcriptional inhibition is distinct from α-defensin-1 HIV inhibition. J. Virol. 77, 6777-6784 (2003).
117. + cell granules. Blood 102, 180-183 (2003).
118. Borregaard, N. & Cowland, J. B. Granules of the human neutrophilic polymorphonuclear leukocyte. Blood 10, 3503-3521 (1997).
119. Mackewicz, C. E. et al. α-defensins can have anti-HIV activity but are not CD8 cell anti-HIV factors. AIDS 17, 23-32 (2003).
120. Zhang, L., Lopez, P., He, T., Yu, W. & Ho, D. D, Retraction of an interpretation. Science 303, 467 (2004).
121. + cell noncytotoxic anti-HIV response can be blocked by protease inhibitors. Proc. Natl Acad. Sci. USA 100, 3433-3438 (2003).
122. Pinto, L. A., Blazevic, V., Shearer, G. M., Patterson, B. K. & Dolan, M. J. Alloantigen-induced anti-HIV activity occurs prior to reverse transcription and can be generated by leukocytes from HIV-infected individuals. Blood 95, 1875-1876 (2000).
123. Fernie, B. F., Poli, G. & Fauci, A. S. α-interferon suppresses virion but not soluble human immunodeficiency virus antigen production in chronically infected T-lymphocytic cells. J. Virol. 65, 3968-3971 (1991).
124. + cells transfected with IL-16 cDNA are resistant to HIV-1 infection: inhibition of mRNA expression. Nature Med. 3, 659-664 (1997).
125. Chen, C. H., Weinhold, K. J., Bartlett, J. A., Bolognesi, D. P. & Greenberg, M. L. CD8 T lymphocyte-mediated inhibition of HIV-1 long terminal repeat transcription: a novel antiviral mechanism. AIDS Res. Hum. Retrovir. 9, 1079-1086 (1993).
126. Mackewicz, C. E., Blackbourn, D. J. & Levy, J. A. CD8 T cells suppress human immunodeficiency virus replication by inhibiting viral transcription. Proc. Natl Acad. Sci. USA 92, 2308-2312 (1995).
127. Copeland, K. F., McKay, P. J. & Rosenthal, K. L. Suppression of activation of the human immunodeficiency virus long terminal repeat by CD8 T cells is not lentivirus specific. AIDS Res. Hum. Retrovir. 11, 1321-1326 (1995).
128. Copeland, K. F., McKay, P. J. & Rosenthal, K. L. Suppression of the human immunodeficiency virus long terminal repeat by CD8 T cells is dependent on the NFAT-1 element. AIDS Res. Hum. Retrovir. 12 143-148 (1996).
129. Leith, J. G. et al. T cell-derived suppressive activity: evidence of autocrine noncytolytic control of HIV type 1 transcription and replication. AIDS Res. Hum. Retrovir. 15, 1553-1561 (1999).
130. Tomaras, G. D. et al. CD8 T cell-mediated suppressive activity inhibits HIV-1 after virus entry with kinetics indicating effects an virus gene expression. Proc. Natl Acad. Sci. USA 97 3503-3508 (2000).
131. Locher, C. P., Witt, S. A. & Levy, J. A. The nuclear factor κB and Spl binding sites do not appear to be involved in virus suppression by CD8 T lymphocytes. AIDS 15, 2455-2457 (2001 ).
132. + cells varies among infected individuals. Cell. Immunol. 119, 470-475 (1989).
133. + cell anti-HIV activity correlates with the clinical state of the infected individual. J. Clin. Invest. 87, 1462-1466 (1991).
134. + cell noncytotoxic anti-HIV response. Proc. Natl Acad. Sci. USA 96, 1030-1035 (1999).
135. + cells correlates with the clinical state of HIV-infected individuals. Proc. Natl Acad. Sci. USA 93, 13125-13130 (1996).
136. Garzino-Demo, A., DeVico A. L. & Gallo, R. C. Chemokine receptors and chemokines in HIV infection. J. Clin. Immunol. 18 243-255 (1998).
137. Garzino-Demo, A., DeVico, A. L., Cocchi, F. & Gallo R. C. β-chemokines and protection from HIV type 1 disease. AIDS Res. Hum. Retrovir. 14 (Suppl.), S177-S184 (1998).
138. Gallo, R. C., Garzino-Demo, A. & DeVico, A. L. HIV infection and pathogenesis: what about chemokines? J. Clin. Immunol. 19 293-299 (1999).
139. Garzino-Demo, A., DeVico, A. L., Conant, K. E. & Gallo R. C. The role of chemokines in human immunodeficiency virus infection. Immunol. Rev. 177, 79-87 (2000).
140. Garzino-Demo, A. et al. Spontaneous and antigen-induced production of HIV-inhibitory β-chemokines are associated with AIDS-free status. Proc. Natl Acad. Sci. USA 96, 11986-11991 (1999).
141. Cocchi, F. et al. Higher macrophage inflammatory protein (MIP)-1α and MIP-1β levels from CD8+ T cells are associated with asymptomatic HIV-1 infection. Proc. Natl Acad. Sci. USA 97 13812-13817 (2000).
142. Liu, H. et al. Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc. Natl Acad. Sci. USA 96, 4581-4585 (1999).
143. McDermott, D. H. et al. Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in the multicenter AIDS cohort study. AIDS 14, 2671-2678 (2000).
144. Gonzales, E. et al. Global survey of genetic variation in CCR5, RANTES, and MIP-1α: impact on the epidemiology of the HIV-1 pandemic. Proc. Natl Acad. Sci. USA 98, 51199-5204 (2001).
145. An, P. et al. Modulating influence on HIV/AIDS by interacting RANTES gene variants. Proc. Natl Acad. Sci. USA 99 10002-10007 (2002).
146. Swiss HIV Cohort Study. Human immunodeficiency virus type 1 fitness is a determining factor in viral rebound and set point in chronic infection. J. Virol. 77, 13146-13155 (2003).
147. + cell clones derived from HIV-infected and uninfected individuals. Cell. Immunol. 159, 271-279 (1994).
148. + T cells from HIV type 1-seronegative individuals suppress virus replication in acutely infected cells. AIDS Res. Hum Retrovir. 13, 79-85 (1997).
149. Levy, J. A., Hsueh, F., Blackbourn, D. J., Wara, D. & Weintrub, P. S. CD8 cell noncytotoxic antiviral activity in human immunodeficiency virus-infected and-uninfected children. J. Infect. Dis. 177, 470-472 (1998).
150. Zagury, D. et al. C-C chemokines, pivotal in protection against HIV type 1 infection. Proc. Natl Acad. Sci. USA 95, 3857-3861 (1998).
151. + lymphocytes from exposed-uninfected individuals: association with low of expression of CCR5 and high production of β -chemokines. Virology 244, 66-73 (1998).
152. Wasik, T. J. et al. Protective role of β-chemokines associated with HIV-specific Th responses against perinatal HIV transmission. J. Immunol. 162, 4355-4364 (1999).
153. + cell noncytotoxic anti-HIV response. Proc. Natl Acad. Sci. USA 96, 1030-1035 (1999).
154. + cells from human immunodeficiency virus type 1 (HIV-1)-infected persons and HIV-1-specific cytotoxic T lymphocytes is not mediated by β-chemokines. J. Virol. 75, 8306-8316 (2001).
155. Skurnick, J. H. et al. Correlates of nontransmission in US women at high risk of human immunodeficiency virus type 1 infection through sexual exposure. J. Infect. Dis. 185, 428-438 (2002).
156. Watt, G., Kantipong, P. & Jongsakul, K. Decrease in human immunodeficiency virus type 1 load during acute dengue fever. Clin. Infect. Dis. 36, 1067-1069 (2003).
157. Watt, G. et al. HIV-1 suppression during acute scrub-typhus infection. Lancet 356, 475-479 (2000).
158. Watt, G., Antipong, P., Jongsakul, K., de Souza, M. & Bumouf, T. Passive transfer of scrub typhus plasma to patients with AIDS: a descriptive clinical study. Q. J. M. 94, 599-607 (2001).
159. Moriuchi, M., Tamura, A. & Moriuchi, H. In vitro reactivation of human immunodeficiency virus-1 upon stimulation with scrub typhus rickettsial infection. Am. J. Trop. Med. Hyg. 68 557-561 (2003).
160. Lefrere, J. J. et al. Carriage of GB virus C/hepatitis G virus RNA is associated with a slower immunologic, virologic, and clinical progression of human immunodeficiency virus disease in coinfected persons. J. Infect. Dis. 179, 783-789 (1999).
161. Yeo, A. E. et al. Effect of hepatitis G virus infection on progression of HIV infection in patients with hemophilia. Multicenter hemophilia cohort study. Ann. Intern. Med. 132, 959-963 (2000).
162. Tillmann, H. L. et al. Infection with GB virus C and reduced mortality among HIV-infected patients. N. Engl. J. Med. 345, 715-724 (2001).
163. Tillmann, H. L. & Manns, M. P. GB virus-C infection in patients infected with the human immunodeficiency virus. Antiviral Res. 52, 83-90 (2001).
164. Nattermann, J. et al. Regulation of CC chemokine receptor 5 in hepatitis G virus infection. AIDS. 17, 1457-1462 (2003).
165. Moss, W. J. et al. Suppression of human immunodeficiency virus replication during acute measles. J. Infect. Dis. 185, 1035-1042 (2002).
166. Kokkotou, E. G. et al. In vitro correlates of HIV-2-mediated HIV-1 protection. Proc. Natl Acad. Sci. USA 97 6797-6802 (2000).
167. Casoli, C. et al. HTLV-II down-regulates HIV-1 replication in IL-2-stimulated primary PBMC of coinfected individuals through expression of MIP-1α. Blood 95, 2760-2769 (2000).
168. + T cells. Nature 417, 95-98 (2002).
169. Valentin, A. et al. Persistent HIV-1 infection of natural killer cells in patients receiving highly active antiretroviral therapy. Proc. Natl Acad. Sci. USA 99, 7015-7020 (2002).
170. Mancini, M., Hadchouel, M., Tiollais, P. & Michel, M. L. Regulation of hepatitis B virus mRNA expression in a hepatitis B surface antigen transgenic mouse model by IFN-γ-secreting T cells after DNA-based immunization. J. Immunol. 161, 5564-5570 (1998).
171. Couillin, I. et al. Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens. J. Infect. Dis. 180, 15-26 (1999).
172. Ren, F., et al. Cytokine-dependent anti-viral role of CD4-positive T cells in therapeutic vaccination against chronic hepatitis B viral infection. J. Med. Virol. 71, 376-384 (2003).
173. Heredia, A. et al. Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV β-chemokines: an approach to suppress R5 strains of HIV-1. Proc. Natl Acad. Sci. USA 100, 10411-10416 (2003).
174. Heredia, A. et al. Induction of G1 cycle arrest in T lymphocytes results in increased extracellular levels of β -chemokines: a strategy to inhibit R5 HIV-1. Proc. Natl Acad. Sci. USA 100, 4179-4184 (2003).
175. + cells from infected and uninfected chimpanzees. Cell. Immunol. 132, 246-255 (1991).
176. + cells from HIV-2-infected baboons control HIV replication. AIDS 11, 737-746 (1997).
177. + lymphocytes. J. Immunol. 140, 2237-2242 (1988).
178. + T lymphocytes from macaques immunized with attenuated SIV. J. Virol. 72, 6315-6324 (1988).
179. Heeney, J. L. et al. β-chemokines and neutralizing antibody titers correlate with sterilizing immunity generated in HIV-1 vaccinated macaques. Proc. Natl Acad. Sci. USA 95, 10803-10808 (1988).
180. + lymphocyte antiviral activity in monkeys immunized with SIV recombinant poxvirus vaccines: potential role in vaccine efficancy. AIDS Res. Hum. Retrovir. 15, 461-470 (1999).
181. Heeney, J. et al. HIV-1 vaccine-induced immune responses which correlate with protection from SHIV infection: compiled preclinical efficacy datafrom trials with ten different HIV-1 vaccine candidates. Immunol. Lett. 66, 189-195 (1999).
182. Ahmed, R. K. et al. β-chemokine production in macaques vaccinated with live attenuated virus correlates with protection against simian immunodeficiency virus (SIVsm) challenge. J. Gen. Virol. 80, 1569-1574 (1999).
183. Lehner, T., et al. Up-regulation of β-chemokines and down-modulation of CCR5 co-receptors inhibit simian immunodeficiency virus transmission in non-human primates. Immunology 99, 569-577 (2000).
184. Ahmed, R. K. et al. Spontaneous production of RANTES and antigen-specific IFN-γ production in macaques vaccinated with SHIV-4 correlates with protection against SIVsm challenge. Clin. Exp. Immunol. 129, 11-18 (2002).
185. + T cell-derived chemokines, HIV suppressor factors and resistance to HIV infection in women. Nature Med. 5, 1004-1009 (1999).